Ifosfamide combined with venorelbine in patients with nasopharyngeal carcinoma refractory to platinum based chemotherapy
- VernacularTitle:异环磷酰胺联合长春瑞滨治疗对铂类耐药的复发和/或转移性鼻咽癌
- Author:
Gengsheng YU
;
Huazhu LU
;
Xiuxin LIN
- Publication Type:Journal Article
- Keywords:
Ifosfamide;
Venorelbine;
Nasopharyngeal carcinoma;
Platinum
- From:
Cancer Research and Clinic
2001;0(04):-
- CountryChina
- Language:Chinese
-
Abstract:
Objective To study the effectiveness and toxicity of ifosfamide(IFO) combined with venorelbine(VRL) in patients with nasopharyngeal carcinoma(NPC) refractory to platinum based chemotherapy. Methods The chemotherapy protocol consisted of intravenous infusion of IFO at the dose of 1200 mg/m2 from day 1 to day 5 with uroprotection of Mesna in infusion at 0,3,6 hours following initiation of IFO and VRL at the dose of 25 mg/m2 at day 1 and day 5. The protocol was repeated every 3 weeks. All patients received at least 2 cycles of chemotherapy. Results Among 25 patients enrolled into the study, 2 patients achieved complete remission, 12 patients achieved partial remission with an total remission rate of 56.0 % and 8 patients had stable disease with clinical benefit rate of 88.0 %. 3 patients had disease progression. Median time to progression was 7.1 months(range:2.0～21.0 months) and 1-year survival rate was 55 %. The main toxicities were myelotoxicity and phlebitis. Conclusion The results indicate that IFO combined with VRL in patients with NPC refractory to platinum based chemotherapy has moderate activity ascompany with tolerable toxicities.
